![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1654191
¹Ì±¹ÀÇ ÃéÀå¾Ï Ä¡·á ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : À¯Çüº°, Ä¡·á¹ýº°, À¯Åë ä³Îº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel, And Segment Forecasts, 2025 - 2030 |
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ ÃéÀå¾Ï Ä¡·á ½ÃÀåÀº 2030³â±îÁö 20¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025-2030³â µ¿¾È CAGRÀº 12.02%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº ÃéÀå¾ÏÀÇ À¯º´·üÀÇ »ó½Â, Á¾¾çÇÐ ¿¬±¸ ÀÚ±Ý Á¦°ø Áõ°¡, ½Å±Ô Ä¡·áÀÇ FDA ½ÂÀÎ µîÀÔ´Ï´Ù. ÀÌȯÀ² »ó½Â, ³ëÈ, Ä¡·á Áøº¸, °ß°íÇÑ ÀÇ·á ÀÎÇÁ¶ó°¡ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
ÃéÀå¾ÏÀº °¡Àå ħ°ø¼ºÀÌ ³ô°í Ä¡»çÀûÀÎ ¾Ï Áß ÇϳªÀ̸ç, »ýÁ¸À²ÀÌ ³·À½ÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ±×·¯³ª Ç¥Àû Ä¡·á, ¸é¿ª Ä¡·á ¹× ¼ö¼úÀÇ ÃÖ±Ù µ¿ÇâÀºÀÌ Áúº´À» °ü¸®Çϱâ À§ÇÑ »õ·Î¿î ½Ã´ë¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÃéÀå¾Ï Ä¡·á ¿É¼Ç¿¡´Â ¼ö¼ú, ÈÇÐ Ä¡·á, ¹æ»ç¼± Ä¡·á, Ç¥Àû Ä¡·á ¹× ¸é¿ª Ä¡·á¿Í °°Àº »õ·Î¿î Ä¡·á°¡ Æ÷ÇԵ˴ϴÙ. ¼ö¼ú ÀýÁ¦´Â ¿©ÀüÈ÷ À¯ÀÏÇÑ ±ÙÄ¡Àû ¼±ÅÃÀÌÁö¸¸ ¸»±â Áø´ÜÀ» À§ÇØ 10-20%ÀÇ È¯ÀÚ¸¸ ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ÈÇÐ ¿ä¹ý, ƯÈ÷ FOLFIRINOX¿Í °°Àº °×½ÃŸºó ±â¹ÝÀÇ º´¿ë ¿ä¹ýÀÌ Ç¥ÁØ ¿ä¹ýÀ¸·Î °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, KRAS³ª BRCA1/2 µîÀÇ À¯ÀüÀÚ º¯ÀÌ¿¡ ÃÊÁ¡À» ¸ÂÃá Ç¥Àû Ä¡·á³ª üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦¿Í °°Àº ¸é¿ªÄ¡·á Á¢±Ù¹ýÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.
¹Ì±¹ÀÇ ÃéÀå¾Ï Ä¡·á ½ÃÀå¿¡¼ À¯¸íÇÑ ±â¾÷À¸·Î´Â Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, Amgen Inc. µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ È¸»çµéÀº ¿¬±¸ °³¹ß¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖÀ¸¸ç, ¿©·¯ °¡Áö »õ·Î¿î Ä¡·á¹ýÀ» °³¹ß ÁßÀÔ´Ï´Ù. Áøº¸¿¡µµ ºÒ±¸Çϰí, ½ÃÀåÀº ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. Áø´ÜÀÌ Áö¿¬µÇ¸é ¸¹Àº ȯÀÚ¿¡°Ô Ä¡·á ¿É¼ÇÀÌ Á¼¾ÆÁöÁö¸¸ °í±Þ Ä¡·á¿¡´Â ºñ¿ëÀÌ ¸¹ÀÌ µì´Ï´Ù. °Ô´Ù°¡, ½Å·ÚÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿°¡ ¾ø´Â °ÍÀº Á¶±â ¹ß°ßÀ̳ª °³ÀÎÈ Ä¡·áÀÇ °³¹ßÀ» °è¼Ó ¾ïÁ¦Çϰí ÀÖ½À´Ï´Ù.
¾ÕÀ¸·Î ¹Ì±¹ÀÇ ÃéÀå¾Ï Ä¡·á ½ÃÀåÀº Å©°Ô ÀüÁøÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ³ë·ÂÀº ½Ç¿ëÀûÀÎ µ¹¿¬º¯À̸¦ È®ÀÎÇÔÀ¸·Î½á º¸´Ù °³º°È µÈ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Á¶±â ¹ß°ß ¹× Ä¡·á °èȹÀ» À§ÇÑ ÀΰøÁö´É ±â¹Ý µµ±¸°¡ º¸±ÞµÇ°í ÀÖ´Â ¹Ý¸é, °øµ¿ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê´Â ¾à¹° °³¹ß°ú ÀÓ»ó °Ë»ç¸¦ °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. °ü¹Î ÆÄÆ®³Ê½Êµµ ÃéÀå¾Ï Ä¡·á¿¡¼ ¹ÌÃæÁ· ¿ä±¸¿¡ ´ëÀÀÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
¹Ì±¹ÀÇ ÃéÀå¾Ï Ä¡·á ½ÃÀåÀº º¯ÇõÀûÀÎ ¼ºÀåÀÇ Â¡Á¶¸¦ º¸À̰í ÀÖ½À´Ï´Ù. °úÁ¦°¡ ³²¾ÆÀÖ´Â °Í, ÃÖ÷´Ü ±â¼ú°ú Çõ½ÅÀûÀÎ Ä¡·áÀÇ ÅëÇÕÀº ȯÀÚÀÇ °á°ú °³¼±¿¡ Èñ¸ÁÀ» °¡Á®¿Ô½À´Ï´Ù. Á¦¾àȸ»ç, ¿¬±¸ÀÚ, ÀÇ·á Á¦°ø¾÷ü¸¦ Æ÷ÇÔÇÑ ÀÌÇØ°ü°èÀÚ´Â ÀÌ Ä¡¸íÀûÀÎ Áúº´À» ¾Î°í Àִ ȯÀÚ¿Í °¡Á·ÀÇ Áß¿äÇÑ ¿ä±¸¿¡ ´ëÀÀÇϱâ À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ´ÙÀ½ 10³â°£Àº ÃéÀå¾Ï Ä¡·áÀÇ Àü¸ÁÀ» À籸ÃàÇϰí, ÀÌ ÁúȯÀÇ º¸´Ù ³ªÀº °ü¸®¿¡ ´ëÇÑ »õ·Î¿î Èñ¸Á°ú ±âȸ¸¦ Á¦°øÇÏ´Â °ÍÀÌ ¾à¼ÓµÇ°í ÀÖ½À´Ï´Ù.
The U.S. pancreatic cancer treatment market is anticipated to reach USD 2.01 billion by 2030 and is expected to grow at a CAGR of 12.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of pancreatic cancer, increased funding for oncology research, and FDA approvals for novel therapies. Rising incidence rates, an aging population, therapeutic advances, and robust healthcare infrastructure are key factors influencing the market.
Pancreatic cancer is one of the most aggressive and lethal forms of cancer, characterized by poor survival rates. However, recent developments in targeted therapies, immunotherapies, and surgical procedures are shaping a new era for managing the disease.Treatment options for pancreatic cancer include surgery, chemotherapy, radiation therapy, and emerging therapies such as targeted therapy and immunotherapy. Surgical resection remains the only potential curative option but is viable for only 10-20% of patients due to late-stage diagnosis. Chemotherapy, particularly gemcitabine-based combinations like FOLFIRINOX, continues to be the standard treatment. Meanwhile, targeted therapies focusing on genetic mutations such as KRAS and BRCA1/2 and immunotherapy approaches like checkpoint inhibitors are gaining traction.
Prominent U.S. pancreatic cancer treatment market players include Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, and Amgen Inc. These companies are actively investing in research and development, with several novel therapies in the pipeline.Despite advancements, the market faces several challenges. Late diagnosis limits treatment options for many patients, while the high costs of advanced therapies can be prohibitive. Additionally, the lack of reliable biomarkers continues to hamper early detection and the development of personalized treatments.
Looking forward, the U.S. pancreatic cancer treatment market is poised for significant advancements. Efforts in precision medicine enable more personalized treatments by identifying actionable mutations. Artificial intelligence-based tools for early detection and treatment planning are gaining traction, while collaborative research initiatives are accelerating drug development and clinical trials. Public-private partnerships are also playing a crucial role in addressing unmet needs in pancreatic cancer treatment.
The U.S. pancreatic cancer treatment market is on the cusp of transformative growth. While challenges persist, the integration of cutting-edge technologies and innovative therapies offers hope for improved patient outcomes. Stakeholders, including pharmaceutical companies, researchers, and healthcare providers, are working collaboratively to address the critical needs of patients and families affected by this devastating disease. The next decade promises to reshape the landscape of pancreatic cancer treatment, offering new hope and opportunities for better management of this condition.